# Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: A retrospective and observational study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/etoposide-platinum-plus-anlotinib-for-patients-with-transformed-small-cell-lung/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jianghua Ding,Zhaohui Leng,Hong Gu,Jing Xiang,Yun Song |
| Citations | 0 |
| DOI | 10.21203/rs.3.rs-2522083/v1 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.researchsquare.com/article/rs-2522083/latest.pdf |
| OpenAlex ID | https://openalex.org/W4318825025 |
| Type | preprint |
| Year | 2023 |

## Paper authors

- [Zhaohui Leng](https://scholariq.org/researchers/zhaohui-leng/)
- [Yun Song](https://scholariq.org/researchers/yun-song/)

## Paper journal

- [Research Square](https://scholariq.org/journals/research-square/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.